The sub-field of onco-nephrology has rapidly grown with the proliferation of highly effective cancer therapies and the remarkable improvement in patient survival. Conventional cytotoxic chemotherapy is a backbone of cancer therapy, often employed alone or with targeted agents and immunotherapies.
However, beneficial anti-cancer effects are often complicated by nephrotoxicity, which includes acute and chronic kidney injury. While numerous conventional cytotoxic chemotherapy drugs are nephrotoxic, some of the most common offenders that clinicians encounter are cisplatin, ifosfamide, methotrexate, pemetrexed, gemcitabine, melphalan, and mitomycin C.
Kidney International published a clinical update in Research Highlights on 23 Mar 2026.
The item focuses on Conventional cytotoxic chemotherapy-associated nephrotoxicity.
Review the original article for the full source wording and details.